Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2015-12-08 |
Tiziana Life Sciences (UK) |
£3,831,708 (US$5,771,146 - €5,320,381) |
private placement |
|
Cancer - Oncology |
Private placement |
2015-12-05 |
Allena Pharmaceuticals (USA - MA) |
$53 million |
series C financing round |
|
|
Series C financing round |
2015-12-03 |
Erytech Pharma (France) |
€ 25.4 million |
private placement |
|
Cancer - Oncology - Rare diseases |
Private placement |
2015-12-03 |
EMTherapy consortium (Inventiva (France), 4SC (Germany), Oryzon Genomics (Spain)) |
€4.8 million |
grant |
European Eurostars Programme (EU) |
Cancer - Oncology |
Grant |
2015-12-02 |
Kesios Therapeutics (UK) |
£19 million (€ 26.9 million) |
series A financing round |
Imperial Innovations Group (UK) SV Life Sciences (UK - USA) Abingworth (UK) |
Cancer - Oncology |
Series A financing round |
2015-12-02 |
Santhera Pharmaceuticals (Switzerland) |
CHF 54.8 million (€ 50.2 million) |
private placement |
|
Rare diseases - Genetic diseases - Neuromuscular diseases |
Private placement |
2015-12-02 |
Santhera Pharmaceuticals (Switzerland) |
CHF 54.8 million (€ 50.2 million) |
capital increase |
|
Rare diseases - Genetic diseases - Neuromuscular diseases |
Capital increase |
2015-11-26 |
Immunovia (Sweden) |
SEK 60 million (€ 6.5 million) |
capital increase |
|
Cancer - Oncology - Diagnostic |
Capital increase |
2015-11-25 |
Spark Therapeutics (USA - PA) |
|
private placement |
|
|
Private placement |
2015-11-23 |
Addex Therapeutics (Switzerland) |
CHF666,240 |
grant |
Commission for Technology and Innovation (CTI) (Switzerland) |
|
Grant |
2015-11-20 |
Newron Pharmaceuticals (Italy) |
CHF 5.4 million |
private placement |
|
CNS diseases - Neurological diseases - Neurodegenerative diseases |
Private placement |
2015-11-11 |
Kuros Biosurgery (Switzerland) |
CHF 20 million |
financing round |
LifeCare Partners (Switzerland) LSP Life Sciences Partners (The Netherlands) undisclosed family offices from Germany and Switzerland, Omega Funds (USA - MA) VI Partners (Switzerland) The Swiss Helvetia Fund (Switzerland) |
Bone diseases - Technology - Services |
Financing round |
2015-11-10 |
Curetis (Germany) |
€ 40 million |
IPO |
|
Diagnostic |
IPO |
2015-11-10 |
Advanced Accelerator Applications (France) |
|
IPO |
|
Cancer - Oncology |
IPO |
2015-11-10 |
Miragen Therapeutics (USa - CO) |
$41 million |
series C financing round |
MRL Ventures (USA - MA) Brace Pharma Capital (USA - MA) JAFCO Co (Japan) MP Healthcare Venture Management (USA - MA) Atlas Venture (USA - MA) Boulder Ventures (USA - CO) Remeditex Ventures (USA - TX) Amgen Ventures (USA - CA) |
Cancer - Oncology - Cardiovascular diseases - Fibrotic diseases - Inflammatory diseases |
Series C financing round |
2015-11-05 |
Oasmia Pharmaceutical (Sweden) |
$10.4 million |
IPO |
|
Cancer - Oncology - Veterinary medicine |
IPO |
2015-11-03 |
Mesoblast (Australia) |
|
|
|
|
IPO |
2015-11-03 |
Solid GT (USA - MA) |
$42.5 million |
series B financing round |
Biogen (USA - MA) Perceptive Advisors (USA - NY) Janus Capital Management (USA - CO) private advisors |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Series B financing round |
2015-11-03 |
ElsaLys Biotech (France) |
€ 2.7 million |
series A financing round |
Sofimac Partners (France) IM Europe (France) Crédit Agricole Création (France) |
Cancer - Oncology - Ophtalmological diseases |
Series A financing round |
2015-11-03 |
Myokardia (USA - CA) |
$55.7 million |
IPO |
|
Cardiovascular diseases |
IPO |